Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1644207 | 0.89 | CA2 (0.46) | LMNACA2CA1CA9CA12 | |
| SCHEMBL113366 | 0.80 | CA1 (0.52) | LMNACA2CA1CA9CA12 | |
| SCHEMBL5179012 | 0.78 | LMNA (0.49) | LMNACA2CA1CA9CA12 | |
| SCHEMBL3609619 | 0.78 | GAA (0.40) | CA2CA1CA9CA12CA7 | |
| SCHEMBL30851364 | 0.76 | LMNA (0.43) | LMNACA2CA1CA9CA12 | |
| SCHEMBL22396637 | 0.76 | CA1 (0.39) | CA2CA1GAACES1FFAR4 | |
| SCHEMBL1645227 | 0.75 | CA1 (0.54) | LMNACA2CA1CA9CA12 | |
| SCHEMBL27804376 | 0.74 | CA2 (0.38) | LMNACA2CA1CA9CA12 | |
| SCHEMBL113864 | 0.73 | RAPGEF4 (0.46) | LMNACA2CA1CA9CA12 | |
| SCHEMBL788180 | 0.73 | RAPGEF4 (0.38) | LMNACA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363396-A1 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2011-09-07 | — | — | EP | claimed |
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-18 | — | — | US | claimed |
| CN-101624391-A | Thiophene derivatives as antiviral agents for flavivirus infection | VIROCHEM PHARMA INC | 2010-01-13 | — | — | CN | claimed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | claimed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | claimed |
| CN-1602308-A | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2005-03-30 | — | — | CN | claimed |
| US-20040116509-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SHIRE BIOCHEM INC. (CA) | 2004-06-17 | — | — | US | claimed |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2013-05-16 | — | — | US | disclosed |
| US-8329924-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2012-12-11 | — | — | US | disclosed |
| EP-2363396-A1 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2011-09-07 | — | — | EP | disclosed |
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-18 | — | — | US | disclosed |
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2206709-A2 | Thiophene derivatives as antiviral agents for flavivirus infection | Virochem Pharma Inc. (CA) | 2010-07-14 | — | — | EP | disclosed |
| CN-101624391-A | Thiophene derivatives as antiviral agents for flavivirus infection | VIROCHEM PHARMA INC | 2010-01-13 | — | — | CN | disclosed |
| CN-100509797-C | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2009-07-08 | — | — | CN | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
| CN-1602308-A | Thiophene derivatives as antiviral agents against flavivirus infections | VIRUS CHEM PHARMA INC (CA) | 2005-03-30 | — | — | CN | disclosed |
| US-20040116509-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | SHIRE BIOCHEM INC. (CA) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200553-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | LMNA 2343/4885CA2 3042/4885CA1 4177/4885 |
| US-20130123242-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | HAVCR2, ZC3HAV1, MAVS | LMNA 2343/4885CA2 3042/4885CA1 4177/4885 |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | LMNA 2343/4885CA2 3042/4885CA1 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.